Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DEK/NUP214 SILAC interactormics analysis

ABSTRACT: Among most of leukemogenic fusion proteins the aberrant localization that the translocation partners are forced in when compared to their wt counterparts contributes to leukemogenesis most likely by a sequester of interaction partners. The aim was to disclose the role of localization of DEK/NUP214 and the related sequester of proteins interacting with DEK/NUP214 for the induction t(6;9)- AML. The pathways indispensable for the induction of the leukemogenic phenotype were worked out by comparing the interactome of the full-length fusion protein to that of biologiaclly-dead mutants.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Acute Leukemia

SUBMITTER: Martin Ruthardt

LAB HEAD: Martin Ruthardt

PROVIDER: PXD031885 | Pride | 2022-10-14

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DCinteractomics_RAW_files.zip	Other
	proteinGroups.txt	Txt

Items per page:

1 - 2 of 2

Similar Datasets

XPO1-dependency of DEK::NUP214 leukemia sensitizes against eltanexor

Project description:We aimed to investigate the role of XPO1 in this rare leukemia subtype. ChIP-sequencing was performed for XPO1 and NUP214 (as surrogate for DEK::NUP214 protein), and found co-occupancy of both proteins in putative DEK::NUP214 target genes.

2025-03-28 | GSE270396 | GEO

Gene expression changes induced by eltanexor in the FKH-1 cell line and PDX model

Project description:We aimed to investigate the role of XPO1 in this rare leukemia subtype. RNA-seq was performed in DEK::NUP214 expressing cell line in control and eltanexor-treated samples, an inhibitor of XPO1, to elucidate the genes and pathways involved in DEK::NUP214 AML

2025-03-28 | GSE270397 | GEO

Gene regulation in t(6;9) AML resembles that of FLT3-ITD/NPM1 AML with an altered HOX/MEIS axis [DNase-hypersensitivity]

Project description:Acute Myeloid Leukemia (AML) represents a heterogeneous group of hematological malignancies. The t(6;9)(p23;q34) translocation, giving rise to the DEK::NUP214 fusion protein, is a rare mutation which produces a highly aggressive AML associated with extremely poor prognosis. Here, we utilise genome-wide chromatin accessibility to elucidate how a normal gene regulatory networks is disrupted by DEK::NUP214. We find that DEK::NUP214 AML forms a specific GRN related to that of mutant NPM1 AML, but also displays an elevated leukemic stem cell signature, suggesting both similar and unique therapeutic vulnerabilities.

2024-01-04 | GSE240268 | GEO

Gene regulation in t(6;9) AML resembles that of FLT3-ITD/NPM1 AML with an altered HOX/MEIS axis [RNA-seq]

2024-01-04 | GSE240267 | GEO

Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming [CUT&Tag]

Project description:Leukemia stem cells (LSCs) drive acute myeloid leukemia (AML) initiation, relapse, and chemoresistance, yet the core post-translational events governing LSC formation and maintenance remain elusive. Here, through phosphoproteomic profiling of normal hematopoietic stem and progenitor cells (HSPCs) versus LSC-enriched population, we identify DEK phosphorylation as a critical modification during leukemogenesis. Functional studies in MLL-AF9- and HOXA9/MEIS1-driven AML mouse models, as well as patient-derived xenografts (PDXs), demonstrate that DEK deficiency impairs LSC maintenance and AML development. Moreover, DEK deletion enhances LSC chemosensitivity to the standard-of-care combination of azacitidine and venetoclax (Aza/Ven), whereas DEK overexpression confers robust chemoresistance. Mechanistically, DEK recruits the transcription factor GABPA to drive overexpression of transcriptional cofactor PBX3, a key oncogenic driver in AML, thereby sustaining a leukemogenic transcriptional program. This DEK-GABPA interaction strictly depends on DEK phosphorylation at Ser301/303/306/307 (the 4S site), which stabilizes the conformation of the DEK-GABPA complex. We demonstrate CK2 as the upstream kinase that directly phosphorylates DEK-4S site. Importantly, inhibition of DEK phosphorylation through 4S site mutations or treatment with a clinical-stage CK2 inhibitor CX-4945 selectively depletes LSCs while sparing normal HSPCs. Furthermore, combining CX-4945 with venetoclax promotes LSC apoptosis and suppresses the PBX3-mediated leukemogenic transcriptional program, exhibiting synergistic anti-AML effects both in vitro and in vivo. Collectively, our findings uncover a previously unrecognized phosphorylation event (DEK-4S phosphorylation) that sustains LSCs and establish the CK2-DEK axis as a promising LSC-specific therapeutic strategy in AML.

2025-09-30 | GSE309284 | GEO

Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming [ATAC-seq]

2025-09-30 | GSE309177 | GEO

Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming [CUT&Tag 2]

2026-04-28 | GSE329274 | GEO

Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming [ATAC-seq 2]

2026-04-28 | GSE329270 | GEO

XPO1-dependency of DEK::NUP214 leukemia sensitizes against eltanexor

Project description:XPO1-dependency of DEK::NUP214 leukemia sensitizes against eltanexor

| PRJNA1126303 | ENA

Gene expression changes upon knockdown of DEK in the U937 cell line

Project description:Gene expression profiling of U937 cells upon knockdown of the DEK oncogene by two different shRNAs (shDEK14 and shDEK17). The DEK oncogene was knocked down by shRNA to study the changes in gene expression.

2014-09-26 | E-GEOD-60732 | biostudies-arrayexpress